Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 4/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19855991 | 0.97 | RAB9A (0.43) | RAB9ACYP2C9GPR119S1PR3LMNA | |
| SCHEMBL19853908 | 0.97 | RAB9A (0.43) | RAB9ARARBCYP2C9GPR119P2RY14 | |
| SCHEMBL19855875 | 0.94 | RAB9A (0.46) | RAB9ACYP2C9GPR119S1PR3LMNA | |
| SCHEMBL19855051 | 0.93 | RAB9A (0.45) | RAB9ACYP2C9GPR119S1PR3LMNA | |
| SCHEMBL19855818 | 0.89 | RAB9A (0.45) | RAB9ACYP2C9GPR119S1PR3LMNA | |
| SCHEMBL19854024 | 0.89 | RAB9A (0.38) | RAB9AGPR119P2RY14BCHE | |
| SCHEMBL19854618 | 0.89 | BTK (0.38) | RAB9AP2RY14BCHE | |
| SCHEMBL19854626 | 0.88 | BTK (0.41) | RAB9ARARBCYP2C9P2RY14 | |
| SCHEMBL19854039 | 0.88 | BTK (0.37) | RAB9AP2RY14BCHEALDH1A1 | |
| SCHEMBL19855104 | 0.87 | RARB (0.41) | RARBGPR119BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, MBD2, PAXBP1 | RAB9A 4014/4885RARB 1437/4885CYP2C9 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.